Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT05093855 |
| Consolidated Lead Sponsor | Staidson (Beijing) Biopharmaceuticals Co |
| Therapeutic Condition Cohort | Immunology, Rheumatology, and Dermatology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | COMPLETED |
| Registered Enrollment | 41 participants (ACTUAL) |
| Registered Start Date | 2021-08-18 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Peking University First Hospital | Beijing, China | Open Hospital Dossier -> |
| Xiangya Hospital Central South University | Changsha, China | Open Hospital Dossier -> |
| The First Hospital of China Medical University | Shenyang, China | Open Hospital Dossier -> |
| The Second Affiliated Hospital of Xi'an Jiaotong University, | Xi’an, China | Open Hospital Dossier -> |
Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.